Vaso Corporation
Vaso Corporation (VASO) Stock Competitors & Peer Comparison
See (VASO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VASO | $0.23 | -6.94% | 39.6M | 22.50 | $0.01 | N/A |
| PMCUF | $89.11 | +3.03% | 9.3B | 55.70 | $1.60 | +0.48% |
| MTHRY | $4.42 | +4.74% | 5.9B | 19.26 | $0.23 | +4.77% |
| MTHRF | $8.55 | +0.00% | 5.7B | 18.59 | $0.46 | +1.62% |
| PANHF | $1.34 | -4.68% | 2.9B | 134.40 | $0.01 | N/A |
| CMPVF | $33.66 | +11.64% | 1.7B | 58.03 | $0.58 | +1.92% |
| PIAHY | $3.00 | +0.00% | 1.6B | 60.00 | $0.05 | N/A |
| CMPUY | $23.00 | -7.26% | 1.2B | 38.98 | $0.59 | N/A |
| RSLBF | $24.63 | +0.00% | 844.2M | 34.68 | $0.71 | +1.76% |
| CRWRF | $24.20 | +0.00% | 828.5M | 44.00 | $0.55 | +1.83% |
Stock Comparison
VASO vs PMCUF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PMCUF has a market cap of 9.3B. Regarding current trading prices, VASO is priced at $0.23, while PMCUF trades at $89.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PMCUF's P/E ratio is 55.70. In terms of profitability, VASO's ROE is +0.06%, compared to PMCUF's ROE of +0.73%. Regarding short-term risk, VASO is more volatile compared to PMCUF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check PMCUF's competition here
VASO vs MTHRY Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MTHRY has a market cap of 5.9B. Regarding current trading prices, VASO is priced at $0.23, while MTHRY trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MTHRY's P/E ratio is 19.26. In terms of profitability, VASO's ROE is +0.06%, compared to MTHRY's ROE of +0.13%. Regarding short-term risk, VASO is less volatile compared to MTHRY. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MTHRY's competition here
VASO vs MTHRF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MTHRF has a market cap of 5.7B. Regarding current trading prices, VASO is priced at $0.23, while MTHRF trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MTHRF's P/E ratio is 18.59. In terms of profitability, VASO's ROE is +0.06%, compared to MTHRF's ROE of +0.17%. Regarding short-term risk, VASO is less volatile compared to MTHRF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MTHRF's competition here
VASO vs PANHF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PANHF has a market cap of 2.9B. Regarding current trading prices, VASO is priced at $0.23, while PANHF trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PANHF's P/E ratio is 134.40. In terms of profitability, VASO's ROE is +0.06%, compared to PANHF's ROE of +0.04%. Regarding short-term risk, VASO is more volatile compared to PANHF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check PANHF's competition here
VASO vs CMPVF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CMPVF has a market cap of 1.7B. Regarding current trading prices, VASO is priced at $0.23, while CMPVF trades at $33.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CMPVF's P/E ratio is 58.03. In terms of profitability, VASO's ROE is +0.06%, compared to CMPVF's ROE of +0.01%. Regarding short-term risk, VASO is less volatile compared to CMPVF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CMPVF's competition here
VASO vs PIAHY Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PIAHY has a market cap of 1.6B. Regarding current trading prices, VASO is priced at $0.23, while PIAHY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PIAHY's P/E ratio is 60.00. In terms of profitability, VASO's ROE is +0.06%, compared to PIAHY's ROE of +0.04%. Regarding short-term risk, VASO is less volatile compared to PIAHY. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check PIAHY's competition here
VASO vs CMPUY Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CMPUY has a market cap of 1.2B. Regarding current trading prices, VASO is priced at $0.23, while CMPUY trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CMPUY's P/E ratio is 38.98. In terms of profitability, VASO's ROE is +0.06%, compared to CMPUY's ROE of +0.01%. Regarding short-term risk, VASO is more volatile compared to CMPUY. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CMPUY's competition here
VASO vs RSLBF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RSLBF has a market cap of 844.2M. Regarding current trading prices, VASO is priced at $0.23, while RSLBF trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RSLBF's P/E ratio is 34.68. In terms of profitability, VASO's ROE is +0.06%, compared to RSLBF's ROE of +0.24%. Regarding short-term risk, VASO is more volatile compared to RSLBF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check RSLBF's competition here
VASO vs CRWRF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CRWRF has a market cap of 828.5M. Regarding current trading prices, VASO is priced at $0.23, while CRWRF trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CRWRF's P/E ratio is 44.00. In terms of profitability, VASO's ROE is +0.06%, compared to CRWRF's ROE of +0.07%. Regarding short-term risk, VASO is less volatile compared to CRWRF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CRWRF's competition here
VASO vs SMSZF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SMSZF has a market cap of 702.6M. Regarding current trading prices, VASO is priced at $0.23, while SMSZF trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SMSZF's P/E ratio is 17.83. In terms of profitability, VASO's ROE is +0.06%, compared to SMSZF's ROE of -0.36%. Regarding short-term risk, VASO is less volatile compared to SMSZF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check SMSZF's competition here
VASO vs KSIOF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, KSIOF has a market cap of 362.6M. Regarding current trading prices, VASO is priced at $0.23, while KSIOF trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas KSIOF's P/E ratio is -378.58. In terms of profitability, VASO's ROE is +0.06%, compared to KSIOF's ROE of -0.13%. Regarding short-term risk, VASO is more volatile compared to KSIOF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check KSIOF's competition here
VASO vs VHIBF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, VHIBF has a market cap of 328.9M. Regarding current trading prices, VASO is priced at $0.23, while VHIBF trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas VHIBF's P/E ratio is 57.78. In terms of profitability, VASO's ROE is +0.06%, compared to VHIBF's ROE of +0.03%. Regarding short-term risk, VASO is more volatile compared to VHIBF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check VHIBF's competition here
VASO vs COGZF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, COGZF has a market cap of 289M. Regarding current trading prices, VASO is priced at $0.23, while COGZF trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas COGZF's P/E ratio is 28.17. In terms of profitability, VASO's ROE is +0.06%, compared to COGZF's ROE of +0.29%. Regarding short-term risk, VASO is more volatile compared to COGZF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check COGZF's competition here
VASO vs SMDCF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SMDCF has a market cap of 280.9M. Regarding current trading prices, VASO is priced at $0.23, while SMDCF trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, VASO's ROE is +0.06%, compared to SMDCF's ROE of N/A. Regarding short-term risk, VASO is more volatile compared to SMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check SMDCF's competition here
VASO vs DLHTF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, DLHTF has a market cap of 254.8M. Regarding current trading prices, VASO is priced at $0.23, while DLHTF trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, VASO's ROE is +0.06%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, VASO is more volatile compared to DLHTF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check DLHTF's competition here
VASO vs VPAHF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, VPAHF has a market cap of 188.2M. Regarding current trading prices, VASO is priced at $0.23, while VPAHF trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, VASO's ROE is +0.06%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, VASO is more volatile compared to VPAHF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check VPAHF's competition here
VASO vs SUSRF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SUSRF has a market cap of 144.9M. Regarding current trading prices, VASO is priced at $0.23, while SUSRF trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SUSRF's P/E ratio is 20.29. In terms of profitability, VASO's ROE is +0.06%, compared to SUSRF's ROE of +0.02%. Regarding short-term risk, VASO is more volatile compared to SUSRF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check SUSRF's competition here
VASO vs ONVVF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ONVVF has a market cap of 122.8M. Regarding current trading prices, VASO is priced at $0.23, while ONVVF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, VASO's ROE is +0.06%, compared to ONVVF's ROE of -2.27%. Regarding short-term risk, VASO is less volatile compared to ONVVF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check ONVVF's competition here
VASO vs RVRC Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RVRC has a market cap of 101.4M. Regarding current trading prices, VASO is priced at $0.23, while RVRC trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RVRC's P/E ratio is -0.35. In terms of profitability, VASO's ROE is +0.06%, compared to RVRC's ROE of +0.07%. Regarding short-term risk, VASO is more volatile compared to RVRC. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check RVRC's competition here
VASO vs CSAMF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CSAMF has a market cap of 98.8M. Regarding current trading prices, VASO is priced at $0.23, while CSAMF trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, VASO's ROE is +0.06%, compared to CSAMF's ROE of -0.85%. Regarding short-term risk, VASO is more volatile compared to CSAMF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CSAMF's competition here
VASO vs TDMMF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, TDMMF has a market cap of 56.2M. Regarding current trading prices, VASO is priced at $0.23, while TDMMF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas TDMMF's P/E ratio is -7.97. In terms of profitability, VASO's ROE is +0.06%, compared to TDMMF's ROE of -0.24%. Regarding short-term risk, VASO is less volatile compared to TDMMF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check TDMMF's competition here
VASO vs HITC Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HITC has a market cap of 52.8M. Regarding current trading prices, VASO is priced at $0.23, while HITC trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HITC's P/E ratio is -14.75. In terms of profitability, VASO's ROE is +0.06%, compared to HITC's ROE of -0.79%. Regarding short-term risk, VASO is more volatile compared to HITC. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check HITC's competition here
VASO vs MDPEF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MDPEF has a market cap of 42.6M. Regarding current trading prices, VASO is priced at $0.23, while MDPEF trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MDPEF's P/E ratio is 0.00. In terms of profitability, VASO's ROE is +0.06%, compared to MDPEF's ROE of N/A. Regarding short-term risk, VASO is more volatile compared to MDPEF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check MDPEF's competition here
VASO vs EMOR Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EMOR has a market cap of 38.3M. Regarding current trading prices, VASO is priced at $0.23, while EMOR trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EMOR's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to EMOR's ROE of +0.06%. Regarding short-term risk, VASO is more volatile compared to EMOR. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check EMOR's competition here
VASO vs TREIF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, TREIF has a market cap of 36.6M. Regarding current trading prices, VASO is priced at $0.23, while TREIF trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas TREIF's P/E ratio is -3.46. In terms of profitability, VASO's ROE is +0.06%, compared to TREIF's ROE of -1.90%. Regarding short-term risk, VASO is less volatile compared to TREIF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check TREIF's competition here
VASO vs CRVW Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CRVW has a market cap of 23.4M. Regarding current trading prices, VASO is priced at $0.23, while CRVW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CRVW's P/E ratio is -4.00. In terms of profitability, VASO's ROE is +0.06%, compared to CRVW's ROE of +0.07%. Regarding short-term risk, VASO is less volatile compared to CRVW. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CRVW's competition here
VASO vs RTNXF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RTNXF has a market cap of 22.5M. Regarding current trading prices, VASO is priced at $0.23, while RTNXF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, VASO's ROE is +0.06%, compared to RTNXF's ROE of +75.44%. Regarding short-term risk, VASO is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check RTNXF's competition here
VASO vs HDSLF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HDSLF has a market cap of 21.1M. Regarding current trading prices, VASO is priced at $0.23, while HDSLF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, VASO's ROE is +0.06%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, VASO is more volatile compared to HDSLF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check HDSLF's competition here
VASO vs THKKF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, THKKF has a market cap of 17.8M. Regarding current trading prices, VASO is priced at $0.23, while THKKF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas THKKF's P/E ratio is -1.51. In terms of profitability, VASO's ROE is +0.06%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, VASO is more volatile compared to THKKF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check THKKF's competition here
VASO vs DGNOF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, DGNOF has a market cap of 14.6M. Regarding current trading prices, VASO is priced at $0.23, while DGNOF trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas DGNOF's P/E ratio is -3.59. In terms of profitability, VASO's ROE is +0.06%, compared to DGNOF's ROE of +30.80%. Regarding short-term risk, VASO is less volatile compared to DGNOF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check DGNOF's competition here
VASO vs MNNDF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MNNDF has a market cap of 14.3M. Regarding current trading prices, VASO is priced at $0.23, while MNNDF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, VASO's ROE is +0.06%, compared to MNNDF's ROE of N/A. Regarding short-term risk, VASO is less volatile compared to MNNDF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MNNDF's competition here
VASO vs PBSV Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PBSV has a market cap of 12.4M. Regarding current trading prices, VASO is priced at $0.23, while PBSV trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PBSV's P/E ratio is -54.00. In terms of profitability, VASO's ROE is +0.06%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, VASO is more volatile compared to PBSV. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check PBSV's competition here
VASO vs CDXFF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CDXFF has a market cap of 9.7M. Regarding current trading prices, VASO is priced at $0.23, while CDXFF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CDXFF's P/E ratio is -1.35. In terms of profitability, VASO's ROE is +0.06%, compared to CDXFF's ROE of +0.70%. Regarding short-term risk, VASO is more volatile compared to CDXFF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CDXFF's competition here
VASO vs BRGX Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, BRGX has a market cap of 8.7M. Regarding current trading prices, VASO is priced at $0.23, while BRGX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas BRGX's P/E ratio is -0.90. In terms of profitability, VASO's ROE is +0.06%, compared to BRGX's ROE of +0.40%. Regarding short-term risk, VASO is more volatile compared to BRGX. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check BRGX's competition here
VASO vs CMPD Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CMPD has a market cap of 8.7M. Regarding current trading prices, VASO is priced at $0.23, while CMPD trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CMPD's P/E ratio is -15.70. In terms of profitability, VASO's ROE is +0.06%, compared to CMPD's ROE of -0.08%. Regarding short-term risk, VASO is less volatile compared to CMPD. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CMPD's competition here
VASO vs CMHSF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CMHSF has a market cap of 8.7M. Regarding current trading prices, VASO is priced at $0.23, while CMHSF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CMHSF's P/E ratio is -3.23. In terms of profitability, VASO's ROE is +0.06%, compared to CMHSF's ROE of +0.41%. Regarding short-term risk, VASO is more volatile compared to CMHSF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CMHSF's competition here
VASO vs HBCNF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HBCNF has a market cap of 8.4M. Regarding current trading prices, VASO is priced at $0.23, while HBCNF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, VASO's ROE is +0.06%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, VASO is less volatile compared to HBCNF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check HBCNF's competition here
VASO vs SPLTF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SPLTF has a market cap of 8M. Regarding current trading prices, VASO is priced at $0.23, while SPLTF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, VASO's ROE is +0.06%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, VASO is less volatile compared to SPLTF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check SPLTF's competition here
VASO vs VYND Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, VYND has a market cap of 7.9M. Regarding current trading prices, VASO is priced at $0.23, while VYND trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas VYND's P/E ratio is -43.00. In terms of profitability, VASO's ROE is +0.06%, compared to VYND's ROE of +0.81%. Regarding short-term risk, VASO is more volatile compared to VYND. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check VYND's competition here
VASO vs UDOCF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, UDOCF has a market cap of 7.6M. Regarding current trading prices, VASO is priced at $0.23, while UDOCF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas UDOCF's P/E ratio is -2.93. In terms of profitability, VASO's ROE is +0.06%, compared to UDOCF's ROE of +62.04%. Regarding short-term risk, VASO is less volatile compared to UDOCF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check UDOCF's competition here
VASO vs AIMLF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, AIMLF has a market cap of 7.4M. Regarding current trading prices, VASO is priced at $0.23, while AIMLF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas AIMLF's P/E ratio is -2.20. In terms of profitability, VASO's ROE is +0.06%, compared to AIMLF's ROE of -5.05%. Regarding short-term risk, VASO is less volatile compared to AIMLF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check AIMLF's competition here
VASO vs WLSS Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, WLSS has a market cap of 6.9M. Regarding current trading prices, VASO is priced at $0.23, while WLSS trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas WLSS's P/E ratio is -249.00. In terms of profitability, VASO's ROE is +0.06%, compared to WLSS's ROE of +0.33%. Regarding short-term risk, VASO is less volatile compared to WLSS. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check WLSS's competition here
VASO vs CRBKF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CRBKF has a market cap of 6.8M. Regarding current trading prices, VASO is priced at $0.23, while CRBKF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, VASO's ROE is +0.06%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, VASO is more volatile compared to CRBKF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CRBKF's competition here
VASO vs DOCRF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, DOCRF has a market cap of 6.2M. Regarding current trading prices, VASO is priced at $0.23, while DOCRF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, VASO's ROE is +0.06%, compared to DOCRF's ROE of -1.12%. Regarding short-term risk, VASO is more volatile compared to DOCRF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check DOCRF's competition here
VASO vs IQAIF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, IQAIF has a market cap of 4.9M. Regarding current trading prices, VASO is priced at $0.23, while IQAIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas IQAIF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to IQAIF's ROE of -0.17%. Regarding short-term risk, VASO is less volatile compared to IQAIF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check IQAIF's competition here
VASO vs CBDS Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CBDS has a market cap of 4.3M. Regarding current trading prices, VASO is priced at $0.23, while CBDS trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CBDS's P/E ratio is -1.49. In terms of profitability, VASO's ROE is +0.06%, compared to CBDS's ROE of +1.34%. Regarding short-term risk, VASO is less volatile compared to CBDS. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CBDS's competition here
VASO vs NDATF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, NDATF has a market cap of 3.3M. Regarding current trading prices, VASO is priced at $0.23, while NDATF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas NDATF's P/E ratio is -8.00. In terms of profitability, VASO's ROE is +0.06%, compared to NDATF's ROE of -0.64%. Regarding short-term risk, VASO is less volatile compared to NDATF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check NDATF's competition here
VASO vs RQHTF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RQHTF has a market cap of 2.6M. Regarding current trading prices, VASO is priced at $0.23, while RQHTF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RQHTF's P/E ratio is -0.07. In terms of profitability, VASO's ROE is +0.06%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, VASO is more volatile compared to RQHTF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check RQHTF's competition here
VASO vs RYAHF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RYAHF has a market cap of 2.2M. Regarding current trading prices, VASO is priced at $0.23, while RYAHF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, VASO's ROE is +0.06%, compared to RYAHF's ROE of +14.95%. Regarding short-term risk, VASO is more volatile compared to RYAHF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check RYAHF's competition here
VASO vs EBYH Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EBYH has a market cap of 1.9M. Regarding current trading prices, VASO is priced at $0.23, while EBYH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EBYH's P/E ratio is -5.42. In terms of profitability, VASO's ROE is +0.06%, compared to EBYH's ROE of +0.14%. Regarding short-term risk, VASO is more volatile compared to EBYH. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check EBYH's competition here
VASO vs MDBIF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MDBIF has a market cap of 1.6M. Regarding current trading prices, VASO is priced at $0.23, while MDBIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MDBIF's P/E ratio is -0.26. In terms of profitability, VASO's ROE is +0.06%, compared to MDBIF's ROE of -0.12%. Regarding short-term risk, VASO is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MDBIF's competition here
VASO vs MDXL Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MDXL has a market cap of 1.2M. Regarding current trading prices, VASO is priced at $0.23, while MDXL trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MDXL's P/E ratio is -0.28. In terms of profitability, VASO's ROE is +0.06%, compared to MDXL's ROE of +0.90%. Regarding short-term risk, VASO is less volatile compared to MDXL. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MDXL's competition here
VASO vs EVAHF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EVAHF has a market cap of 1M. Regarding current trading prices, VASO is priced at $0.23, while EVAHF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EVAHF's P/E ratio is -0.42. In terms of profitability, VASO's ROE is +0.06%, compared to EVAHF's ROE of +0.78%. Regarding short-term risk, VASO is more volatile compared to EVAHF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check EVAHF's competition here
VASO vs EKGGF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EKGGF has a market cap of 908.9K. Regarding current trading prices, VASO is priced at $0.23, while EKGGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EKGGF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to EKGGF's ROE of +1.03%. Regarding short-term risk, VASO is less volatile compared to EKGGF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check EKGGF's competition here
VASO vs CSOC Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CSOC has a market cap of 857.8K. Regarding current trading prices, VASO is priced at $0.23, while CSOC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CSOC's P/E ratio is 0.16. In terms of profitability, VASO's ROE is +0.06%, compared to CSOC's ROE of -4.64%. Regarding short-term risk, VASO is more volatile compared to CSOC. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check CSOC's competition here
VASO vs MDRM Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MDRM has a market cap of 765.3K. Regarding current trading prices, VASO is priced at $0.23, while MDRM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MDRM's P/E ratio is -0.60. In terms of profitability, VASO's ROE is +0.06%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, VASO is more volatile compared to MDRM. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check MDRM's competition here
VASO vs MITI Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MITI has a market cap of 550.2K. Regarding current trading prices, VASO is priced at $0.23, while MITI trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MITI's P/E ratio is -0.37. In terms of profitability, VASO's ROE is +0.06%, compared to MITI's ROE of -0.02%. Regarding short-term risk, VASO is more volatile compared to MITI. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check MITI's competition here
VASO vs MDNWF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MDNWF has a market cap of 517.3K. Regarding current trading prices, VASO is priced at $0.23, while MDNWF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, VASO's ROE is +0.06%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, VASO is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check MDNWF's competition here
VASO vs PPJE Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PPJE has a market cap of 445.2K. Regarding current trading prices, VASO is priced at $0.23, while PPJE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PPJE's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to PPJE's ROE of -0.00%. Regarding short-term risk, VASO is more volatile compared to PPJE. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check PPJE's competition here
VASO vs CTVEF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CTVEF has a market cap of 418.1K. Regarding current trading prices, VASO is priced at $0.23, while CTVEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CTVEF's P/E ratio is -0.16. In terms of profitability, VASO's ROE is +0.06%, compared to CTVEF's ROE of +0.17%. Regarding short-term risk, VASO is less volatile compared to CTVEF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CTVEF's competition here
VASO vs ACHKF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ACHKF has a market cap of 377.4K. Regarding current trading prices, VASO is priced at $0.23, while ACHKF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ACHKF's P/E ratio is -0.05. In terms of profitability, VASO's ROE is +0.06%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, VASO is more volatile compared to ACHKF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check ACHKF's competition here
VASO vs LVCE Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, LVCE has a market cap of 357.2K. Regarding current trading prices, VASO is priced at $0.23, while LVCE trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas LVCE's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to LVCE's ROE of N/A. Regarding short-term risk, VASO is less volatile compared to LVCE. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check LVCE's competition here
VASO vs RSLT Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, RSLT has a market cap of 347.5K. Regarding current trading prices, VASO is priced at $0.23, while RSLT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas RSLT's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to RSLT's ROE of N/A. Regarding short-term risk, VASO is more volatile compared to RSLT. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check RSLT's competition here
VASO vs NHIQ Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, NHIQ has a market cap of 329.7K. Regarding current trading prices, VASO is priced at $0.23, while NHIQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas NHIQ's P/E ratio is -0.00. In terms of profitability, VASO's ROE is +0.06%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, VASO is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check NHIQ's competition here
VASO vs DTRK Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, DTRK has a market cap of 242.8K. Regarding current trading prices, VASO is priced at $0.23, while DTRK trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas DTRK's P/E ratio is -4.75. In terms of profitability, VASO's ROE is +0.06%, compared to DTRK's ROE of +0.37%. Regarding short-term risk, VASO is less volatile compared to DTRK. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check DTRK's competition here
VASO vs USPS Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, USPS has a market cap of 215.1K. Regarding current trading prices, VASO is priced at $0.23, while USPS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas USPS's P/E ratio is -1.36. In terms of profitability, VASO's ROE is +0.06%, compared to USPS's ROE of +0.62%. Regarding short-term risk, VASO is more volatile compared to USPS. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check USPS's competition here
VASO vs EWLL Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EWLL has a market cap of 185.1K. Regarding current trading prices, VASO is priced at $0.23, while EWLL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EWLL's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to EWLL's ROE of +0.13%. Regarding short-term risk, VASO is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check EWLL's competition here
VASO vs ALDNF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ALDNF has a market cap of 160.4K. Regarding current trading prices, VASO is priced at $0.23, while ALDNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ALDNF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to ALDNF's ROE of +0.55%. Regarding short-term risk, VASO is more volatile compared to ALDNF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check ALDNF's competition here
VASO vs TSTTF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, TSTTF has a market cap of 145.8K. Regarding current trading prices, VASO is priced at $0.23, while TSTTF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas TSTTF's P/E ratio is -0.73. In terms of profitability, VASO's ROE is +0.06%, compared to TSTTF's ROE of -0.02%. Regarding short-term risk, VASO is less volatile compared to TSTTF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check TSTTF's competition here
VASO vs EMYSF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, EMYSF has a market cap of 142.2K. Regarding current trading prices, VASO is priced at $0.23, while EMYSF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas EMYSF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to EMYSF's ROE of +2.20%. Regarding short-term risk, VASO is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check EMYSF's competition here
VASO vs DSOL Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, DSOL has a market cap of 88.9K. Regarding current trading prices, VASO is priced at $0.23, while DSOL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas DSOL's P/E ratio is -0.01. In terms of profitability, VASO's ROE is +0.06%, compared to DSOL's ROE of +0.03%. Regarding short-term risk, VASO is less volatile compared to DSOL. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check DSOL's competition here
VASO vs NEWUF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, NEWUF has a market cap of 86.6K. Regarding current trading prices, VASO is priced at $0.23, while NEWUF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas NEWUF's P/E ratio is -0.02. In terms of profitability, VASO's ROE is +0.06%, compared to NEWUF's ROE of +0.88%. Regarding short-term risk, VASO is more volatile compared to NEWUF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check NEWUF's competition here
VASO vs PASO Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PASO has a market cap of 74.1K. Regarding current trading prices, VASO is priced at $0.23, while PASO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PASO's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to PASO's ROE of +6.20%. Regarding short-term risk, VASO is more volatile compared to PASO. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check PASO's competition here
VASO vs LFCOF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, LFCOF has a market cap of 63.4K. Regarding current trading prices, VASO is priced at $0.23, while LFCOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, VASO's ROE is +0.06%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, VASO is more volatile compared to LFCOF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check LFCOF's competition here
VASO vs REFG Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, REFG has a market cap of 60.8K. Regarding current trading prices, VASO is priced at $0.23, while REFG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas REFG's P/E ratio is -0.01. In terms of profitability, VASO's ROE is +0.06%, compared to REFG's ROE of +0.01%. Regarding short-term risk, VASO is more volatile compared to REFG. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check REFG's competition here
VASO vs SOFE Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SOFE has a market cap of 45.1K. Regarding current trading prices, VASO is priced at $0.23, while SOFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SOFE's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, VASO is less volatile compared to SOFE. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check SOFE's competition here
VASO vs HDVY Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HDVY has a market cap of 41.2K. Regarding current trading prices, VASO is priced at $0.23, while HDVY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HDVY's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to HDVY's ROE of +15.89%. Regarding short-term risk, VASO is more volatile compared to HDVY. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check HDVY's competition here
VASO vs IGRW Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, IGRW has a market cap of 39.8K. Regarding current trading prices, VASO is priced at $0.23, while IGRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas IGRW's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to IGRW's ROE of -2.28%. Regarding short-term risk, VASO is less volatile compared to IGRW. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check IGRW's competition here
VASO vs WMGR Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, WMGR has a market cap of 36.3K. Regarding current trading prices, VASO is priced at $0.23, while WMGR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas WMGR's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to WMGR's ROE of +0.53%. Regarding short-term risk, VASO is more volatile compared to WMGR. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check WMGR's competition here
VASO vs SSYNF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, SSYNF has a market cap of 33.3K. Regarding current trading prices, VASO is priced at $0.23, while SSYNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, VASO's ROE is +0.06%, compared to SSYNF's ROE of N/A. Regarding short-term risk, VASO is more volatile compared to SSYNF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check SSYNF's competition here
VASO vs ORHB Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ORHB has a market cap of 27.5K. Regarding current trading prices, VASO is priced at $0.23, while ORHB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ORHB's P/E ratio is -0.02. In terms of profitability, VASO's ROE is +0.06%, compared to ORHB's ROE of +1.70%. Regarding short-term risk, VASO is more volatile compared to ORHB. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check ORHB's competition here
VASO vs TTBLF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, TTBLF has a market cap of 26.7K. Regarding current trading prices, VASO is priced at $0.23, while TTBLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, VASO's ROE is +0.06%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, VASO is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check TTBLF's competition here
VASO vs NMXS Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, NMXS has a market cap of 26.4K. Regarding current trading prices, VASO is priced at $0.23, while NMXS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas NMXS's P/E ratio is -0.07. In terms of profitability, VASO's ROE is +0.06%, compared to NMXS's ROE of -2.50%. Regarding short-term risk, VASO is less volatile compared to NMXS. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check NMXS's competition here
VASO vs FDBH Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, FDBH has a market cap of 25K. Regarding current trading prices, VASO is priced at $0.23, while FDBH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas FDBH's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, VASO is less volatile compared to FDBH. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check FDBH's competition here
VASO vs NHEL Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, NHEL has a market cap of 16.2K. Regarding current trading prices, VASO is priced at $0.23, while NHEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas NHEL's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to NHEL's ROE of +7.36%. Regarding short-term risk, VASO is more volatile compared to NHEL. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check NHEL's competition here
VASO vs BNVIF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, BNVIF has a market cap of 13.3K. Regarding current trading prices, VASO is priced at $0.23, while BNVIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas BNVIF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, VASO is less volatile compared to BNVIF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check BNVIF's competition here
VASO vs HLTT Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HLTT has a market cap of 10.7K. Regarding current trading prices, VASO is priced at $0.23, while HLTT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HLTT's P/E ratio is -0.00. In terms of profitability, VASO's ROE is +0.06%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, VASO is more volatile compared to HLTT. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check HLTT's competition here
VASO vs CGNSF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CGNSF has a market cap of 9K. Regarding current trading prices, VASO is priced at $0.23, while CGNSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CGNSF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, VASO is less volatile compared to CGNSF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CGNSF's competition here
VASO vs MOSTQ Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, MOSTQ has a market cap of 8.5K. Regarding current trading prices, VASO is priced at $0.23, while MOSTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas MOSTQ's P/E ratio is -0.00. In terms of profitability, VASO's ROE is +0.06%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, VASO is more volatile compared to MOSTQ. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check MOSTQ's competition here
VASO vs ACNV Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ACNV has a market cap of 8.1K. Regarding current trading prices, VASO is priced at $0.23, while ACNV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ACNV's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to ACNV's ROE of +0.85%. Regarding short-term risk, VASO is more volatile compared to ACNV. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check ACNV's competition here
VASO vs AHGIF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, AHGIF has a market cap of 7.8K. Regarding current trading prices, VASO is priced at $0.23, while AHGIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas AHGIF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, VASO is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check AHGIF's competition here
VASO vs BBLNF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, BBLNF has a market cap of 2.6K. Regarding current trading prices, VASO is priced at $0.23, while BBLNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas BBLNF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, VASO is more volatile compared to BBLNF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check BBLNF's competition here
VASO vs ICCO Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ICCO has a market cap of 2K. Regarding current trading prices, VASO is priced at $0.23, while ICCO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ICCO's P/E ratio is -0.01. In terms of profitability, VASO's ROE is +0.06%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, VASO is less volatile compared to ICCO. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check ICCO's competition here
VASO vs HSCHF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, HSCHF has a market cap of 1.2K. Regarding current trading prices, VASO is priced at $0.23, while HSCHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas HSCHF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to HSCHF's ROE of +1.98%. Regarding short-term risk, VASO is more volatile compared to HSCHF. This indicates potentially higher risk in terms of short-term price fluctuations for VASO.Check HSCHF's competition here
VASO vs PCYS Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, PCYS has a market cap of 1.1K. Regarding current trading prices, VASO is priced at $0.23, while PCYS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas PCYS's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to PCYS's ROE of -2.71%. Regarding short-term risk, VASO is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check PCYS's competition here
VASO vs CNONF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, CNONF has a market cap of 1.1K. Regarding current trading prices, VASO is priced at $0.23, while CNONF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas CNONF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, VASO is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check CNONF's competition here
VASO vs OLMM Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, OLMM has a market cap of 1K. Regarding current trading prices, VASO is priced at $0.23, while OLMM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas OLMM's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to OLMM's ROE of +4.54%. Regarding short-term risk, VASO is less volatile compared to OLMM. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check OLMM's competition here
VASO vs ETAOF Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, ETAOF has a market cap of 512. Regarding current trading prices, VASO is priced at $0.23, while ETAOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas ETAOF's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, VASO is less volatile compared to ETAOF. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check ETAOF's competition here
VASO vs LGBI Comparison May 2026
VASO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VASO stands at 39.6M. In comparison, LGBI has a market cap of 50. Regarding current trading prices, VASO is priced at $0.23, while LGBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VASO currently has a P/E ratio of 22.50, whereas LGBI's P/E ratio is N/A. In terms of profitability, VASO's ROE is +0.06%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, VASO is less volatile compared to LGBI. This indicates potentially lower risk in terms of short-term price fluctuations for VASO.Check LGBI's competition here